Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over

Sanofi Alum Is New Addition To Executive Committee

Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond. 

Biogen Inc. HQ in Cambridge, MA
Biogen leadership has changed significantly in recent months • Source: Shutterstock

Biogen, Inc.’s new president and CEO Christopher Viehbacher has brought in former Sanofi colleague Adam Keeney to help advance the company’s goal of “sustainable growth” from its existing products and programs as well as from assets sourced externally. Keeney, Biogen’s newly appointed executive vice president and head of corporate development, told Scrip he is encouraged by what the company already is working on and is looking forward to bringing novel therapies into the mix.

But to say that Biogen’s current growth trajectory is in need of a turnaround may be an understatement. The company...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.